🔬 We delivered sustained electrical stimulation through implanted microelectrodes while imaging microglia in living mouse brain. During stimulation, microglial processes extended preferentially toward the neurons that were most active. Not toward the electrode. Toward the activated cells. The immune system was tracking which neurons were working hardest.

🤔 This is fundamentally different from the foreign body response described in Post 3. Scar-forming microglia react to the device as a physical object. These surveillant microglia were responding to the biological consequences of device operation. Two different immune behaviors, triggered by two different signals, operating simultaneously around the same implant.

⚡ The stimulation frequency mattered. At 10 Hz, microglia directed surveillance toward metabolically stressed neurons without triggering classical inflammation. Different frequencies produced different immune responses, a variable no current clinical stimulation protocol accounts for. The same device delivering different pulse patterns could create very different immune environments in surrounding tissue.

🔗 This connects the metabolic story running through the series. Neurons near the electrode are energy-deprived (Post 5). Blood supply is compromised (Post 13). Stimulation itself disrupts neurovascular coupling (Post 14). Now we’re seeing immune cells detect that metabolic stress and respond in real time. The immune, vascular, and metabolic systems aren’t separate problems. They’re one integrated biological response to a device that is both present and active.

🔧 This collapses the boundary between “biocompatibility” and “device function.” Designing stimulation patterns requires considering immune consequences, not just neural ones.

Microglia and stimulation: https://iopscience.iop.org/article/10.1088/1741-2552/ae4652
Immune response review: https://www.nature.com/articles/s41551-017-0154-1

#Neuroscience #Immunology #BrainStimulation #Neurotechnology #BrainComputerInterface

🔬 Using calcium imaging and hemodynamic monitoring in awake mice, we tracked how repeated electrical stimulation changes both neural activity and local blood flow over weeks of chronic stimulation in the visual cortex. This let us watch two things simultaneously: what neurons were doing, and whether the blood supply was keeping up.

📊 The results challenged a core assumption. Chronic stimulation didn’t just activate neurons in the moment. It altered the relationship between neural activity and blood flow over time. The hemodynamic signals, the brain’s way of directing fuel to active regions, shifted in ways that persisted beyond each stimulation session. The coupling between “neurons need energy” and “blood delivers energy” became less reliable with repeated use.

🚨 Think of it this way. Your brain has a thermostat that matches energy delivery to energy demand in real time. When neurons fire more, blood flow increases to feed them. Our data show that repeated stimulation disrupts that matching. The thermostat starts misreading the room. Neurons are working hard, but the fuel delivery system isn’t responding proportionally.

😶 This creates a problem layered on top of everything this series has described. The implant already disrupts blood flow through vessel damage during insertion (Post 1). Pericytes constrict and stay constricted for weeks (Post 13). The foreign body response creates a metabolically hostile environment (Post 3). Now we’re showing that the therapeutic stimulation itself, the very thing the device is designed to do, may further alter the metabolic environment it depends on. The failures compound.

🧩 This also connects to the finding that stimulation can recruit inhibitory networks in unexpected ways (Post 7). If the blood supply can’t keep pace with what stimulation demands, neurons may fatigue not because the stimulation pattern is wrong, but because the metabolic infrastructure can’t support it.

🔧 Designing stimulation that works long-term may require monitoring not just whether neurons respond, but whether the energy supply can sustain what we’re asking those neurons to do. The brain isn’t just a circuit. It’s a circuit with a power bill.

Chronic ICMS hemodynamics: https://www.sciencedirect.com/science/article/pii/S0142961226003005
Energy crisis: https://bioniclab.substack.com/p/the-energy-crisis-nobody-talks-about
Review: https://iopscience.iop.org/article/10.1088/1741-2552/ae54cf/

#Neuroscience #BrainStimulation #Neurotechnology #BrainComputerInterface #Bioengineering

A common pattern across engineering-and-biology conversations in BCI translation runs like this. Investigator demonstrates that mechanism A is sufficient to drive outcome B, with an intervention experiment that perturbs A and watches B change. Critic responds, “you have not shown A is the only cause, B also depends on C, D, E.” Investigator agrees that C, D, E matter. Critic concludes the experiment proves nothing.

⚡ The confusion is between three distinct logical operators. Sufficiency, if A, then B. Necessity, B requires A. Exclusivity, only A produces B. Most intervention experiments demonstrate sufficiency. Almost no one claims exclusivity, because biology rarely runs through a single pathway. But engineers trained on system identification often treat sufficiency claims as exclusivity claims, because in a well-characterized linear system, finding one input-output transfer function is supposed to be the answer.

🔬 Biological systems do not work that way. Multiple independent pathways can produce the same phenotype. Sir Austin Bradford Hill made this explicit in the 1965 Proceedings of the Royal Society of Medicine paper that founded modern causal inference in medicine (link below), arguing that intervention evidence should be weighed against the reality of multiple causes rather than held to a standard of demonstrating sole causation.

📊 The cost of confusing sufficiency with exclusivity is measurable. For chronic intracortical recording, the field has spent over two decades targeting neuron protection (anti-inflammatory coatings, softer materials, smaller electrodes) on the assumption that neuron death drives signal loss. Recent genetic-perturbation work shows that oligodendrocyte metabolic support gates recording quality at chronic-implant inflammatory baseline, independent of neuron loss. Inflammation matters. Neuron death matters. Oligodendrocyte function matters. They are not the same variable, and intervention on any of them can change the recording outcome.

🔧 The translational question is not “what is the unique cause” but “what is a tractable intervention point.” Sufficient cause is not the cause. It is a cause. Demonstrating that A is sufficient says A is an axis you can move to change the output, which is what therapeutic strategy actually requires.

🇺🇸 The decades-long mistargeting of BCI intervention strategy comes not from bad science but from a logical category error that Hill warned against sixty years ago. Sufficient cause is not the cause. It is a cause. That distinction is worth recovering.

Hill 1965 (free): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1898525/

#WhyBCIsFail #Neuroscience #BrainComputerInterface #CausalInference #NeuralEngineering

🔬 Your brain has its own plumbing system. Capillaries deliver oxygen and fuel to neurons, and wrapped around them are mural cells, pericytes and smooth muscle cells that act as valves, opening and closing to direct blood where it’s needed. Without them, the brain has no way to route fuel to active regions.

🚨 When an electrode is implanted, pericytes near the device constrict, squeezing capillaries shut. Blood flow to nearby neurons drops. Not because vessels were destroyed during insertion, but because the biological valves controlling flow clamped down in response to injury and stayed shut.

📊 We tracked individual pericytes on individual capillaries for weeks after implantation using two-photon microscopy. The mural cells didn’t just react once and recover. They changed structurally over time, shifting their shape, position, and grip on the vessels they regulate. Some that initially constricted never fully relaxed. Others migrated away from their normal positions along the capillary wall. The blood supply restriction wasn’t a one-time injury. It was an evolving problem that worsened even as the initial insertion wound healed.

🧠 This matters because neurons are energy hogs that can’t stockpile fuel. When blood flow drops even modestly, they lose the ability to sustain activity. They don’t die. They go quiet, rationing energy the way any system does when supply is constrained (Post 5 on the energy crisis).

🔗 Connect this to the timeline from earlier posts. The electrode severs vessels on insertion (Post 1). Immune cells swarm within hours (Post 3). Oligodendrocytes that keep neurons metabolically efficient are damaged within days (Post 4). Now we’re showing that the vascular cells responsible for restoring blood flow are themselves compromised for weeks. Each layer of the response compounds the last.

🔧 The device might be fine. The wiring might be fine. But the power grid went down. If we want implants that last decades, we need strategies that protect the brain’s plumbing, not just its circuitry.

Mural cells: https://www.sciencedirect.com/science/article/pii/S0142961224004988
Energy crisis: https://bioniclab.substack.com/p/the-energy-crisis-nobody-talks-about
Review: https://iopscience.iop.org/article/10.1088/1741-2552/ae54cf/

#Neuroscience #Neurotechnology #BrainComputerInterface #Bioengineering #BrainHealth

🔬 We found it in mouse neurons within weeks of electrode implantation.

🔋 The mechanism is metabolic. Lysosomes, the cell’s recycling organelles, digest damaged proteins using a highly acidic internal environment maintained by an ATP-consuming proton pump. When ATP runs short, the pump slows, acidity falls, digestive enzymes stop working, and waste accumulates as lipofuscin. We confirmed this directly: lysosomal enzyme activity and acidification were disrupted in cells near chronically implanted electrodes, tracking with proximity and metabolic stress.

🪫 Around a chronically implanted electrode, the conditions driving that energetic shortage are everywhere. Reduced tissue oxygenation from vascular disruption (Post 5). Pericytes clamping capillaries shut for weeks (Post 13). Demyelinated axons burning ATP faster than it can be replenished (Posts 10, 12). The neurons closest to the electrode are running an energy deficit they cannot dig out of. The lipofuscin is the cellular receipt for that deficit, frozen in place.

⚠️ This is not aging in the chronological sense. The mice are young. But at the cellular level, neurons near the electrode carry the waste burden of a cell decades older than they are. They look alive. They are structurally intact. They are also functionally compromised in ways that appear in recordings as silenced or unreliable units.

🚨 Lysosomal dysfunction is a central feature of Alzheimer’s, Parkinson’s, and ALS. The cellular pathway near an implanted electrode overlaps directly with pathways that drive neurodegeneration. That is why the APP/PS1 mice from Post 8 develop plaques months ahead of schedule when implanted. The electrode didn’t cause Alzheimer’s. It accelerated a degenerative cascade that was already primed, and lysosomal failure is the mechanism connecting metabolic stress to disease progression.

🔧 The intervention target is metabolic. Restore the energy supply, and lysosomes can resume function before waste accumulates past recovery. That is the window we are trying to characterize, the line between a silenced neuron that can come back and one that can’t.

🕰️ The trash piles up quietly. By the time you see it in your recordings, the cell has already aged decades.

Lysosomal dysfunction: https://www.sciencedirect.com/science/article/pii/S0142961223003241

Metabolic stress: https://pubs.acs.org/doi/full/10.1021/cn500256e

Alzheimer’s connection: https://iopscience.iop.org/article/10.1088/1741-2552/aceca5/

Why BCIs Fail Series: https://bioniclab.substack.com

#Neuroscience #Neurodegeneration #BrainHealth #Neurotechnology #BrainComputerInterface #BrainAging

🔬 We engineered mice in which we could selectively alter a single non-neuronal cell type, oligodendrocytes, while leaving every neuron completely untouched. Same electrode. Same surgery. Same brain region. Same neurons. The only variable was the health of the cells that wrap and insulate nerve fibers, the cells most BCI engineers have never considered a target.

📊 The results were unambiguous. Mice with healthier oligodendrocytes maintained sharper single-neuron signals over the chronic recording period. The fidelity of individual units, how cleanly we could isolate one neuron’s voice from the crowd, was better preserved. Network-level dynamics were more stable. The neurons were identical across both groups. The oligodendrocytes made the difference.

💡 This is causal evidence, not correlation. Not “oligodendrocytes happen to be damaged near failing electrodes.” Not “a drug that helps oligodendrocytes also helps recordings” (Post 11). This is: change one cell type genetically, hold everything else constant, and recording quality changes with it. The link runs directly through cells the field has treated as background infrastructure.

🔗 The causal chain connects the last several posts. The energy crisis (Post 5) showed neurons going silent from metabolic stress. Post 10 explained that oligodendrocytes dramatically reduce the energy cost of neural firing. Post 11 showed a drug targeting oligodendrocytes improved recording stability. Now the genetic proof closes the loop: oligodendrocyte health directly determines whether neurons can sustain the firing patterns that carry information for a BCI decoder.

🔧 The field has spent decades engineering better ways to protect neurons from implants. Our data say the neurons were never the weakest link. The support cells were. The target for next-generation BCI longevity isn’t the electrode surface. It’s the cellular neighborhood.

Genetic proof: https://iopscience.iop.org/article/10.1088/1741-2552/ae4d8b
Oligodendrocyte review: https://www.sciencedirect.com/science/article/pii/S0142961218306069

#Neuroscience #Neurotechnology #BrainComputerInterface #GlialCells #Bioengineering

We chose Clemastine, an antihistamine that has been shown in other contexts to promote oligodendrocyte differentiation and myelination. It is FDA-approved, orally administered, crosses the blood-brain barrier, and has a known safety profile. It targets signaling pathways specific to oligodendrocytes through muscarinic receptors. If you wanted to test the oligodendrocyte hypothesis in a living brain, it was a reasonable tool.

📈 The results were striking. In mice receiving Clemastine starting one week before electrode implantation, myelin levels near the electrode were roughly 180% of controls. Chronic recording stability improved by approximately 140%. Critically, inhibitory neuronal activity, the first thing to degrade in our recordings without intervention, was substantially better preserved.

🧫 Demonstrating that a drug targeting oligodendrocytes improves chronic BCI recording requires a living brain, a functioning immune system, intact vasculature, and months of electrophysiology, conditions no current non-animal model (NAMs) can provide.

⚠️ I want to be careful about how I frame this. Clemastine is not a BCI treatment. These are rodent experiments, and translation from rodent to human is never guaranteed. The appropriate response to these findings is not to start taking Clemastine before a BCI surgery. It is to take the oligodendrocyte hypothesis seriously as a target, fund research to understand the mechanism more deeply, and explore whether this or related compounds have a role in improving device longevity in humans.

🔎 But the experiment taught us something beyond the drug effect. The fact that a pharmacological intervention targeting a non-neuronal cell type, not neurons, not the electrode surface, not the biomaterial coating, could meaningfully change recording performance is itself important. It tells us that the failure we observe in chronic BCI recordings is not purely a materials problem or a surgical problem. It is partly a cellular biology problem. And cellular biology problems have biological solutions.

👨‍👩‍👧‍👦 The field has spent enormous resources making better electrodes. We may also need to make better biological neighborhoods for those electrodes to live in.

Clemastine: https://lnkd.in/eyNPriA9
Fus in Oligo: https://lnkd.in/eFErQ2i9

#Neuroscience #DrugDiscovery #Neurotechnology #BrainComputerInterface #Bioengineering

🧩 That explanation is correct. It is also, we believe, incomplete in a way that has misled the BCI field for years.

🔋 If speed were the primary function of myelination, you would expect that depleting myelin would slow neural signals. And it does, but only modestly, and only for the third+ action potential in a sequence. What changes dramatically when myelin is lost is not the speed of individual spikes but the ability of neurons to sustain high firing rates over time.

🪫 We showed this by depleting oligodendrocytes using a well-established pharmacological model. Neurons in the demyelinated cortex showed normal or near-normal latency for single evoked responses. But ask those same neurons to sustain elevated activity for more than 400 milliseconds, and they failed. They fatigued in a way that myelinated neurons did not.

⚡ The mechanism is metabolic. Maintaining myelin is energetically expensive. Evolution does not make that investment without a return. The return is not primarily speed. It is the dramatic reduction in the metabolic cost of sustained firing. By restricting ion exchange to the nodes of Ranvier, myelin reduces the total sodium and potassium flux during an action potential, which reduces the ATP required to restore the ion gradients afterward.

💡 For BCIs, the implication is direct. A device implanted in a region where oligodendrocytes have been injured or depleted is not just recording from neurons in a hostile chemical environment. It is recording from neurons that have lost their metabolic efficiency, neurons that can respond to a brief stimulus but cannot sustain the patterns of activity that make their signals informationally rich. In contrast, reinforcing myelin with genetic manipulation or drugs can help preserve energy efficiency and function.

🖨️ Fixing the recording problem may require fixing the oligodendrocyte problem first.

Review: https://lnkd.in/edpJ2zzy
Oligo: https://lnkd.in/ePXYRr2C
Fatigue: https://lnkd.in/egAwPGv
Network Stability: https://lnkd.in/eFErQ2i9
Drugs: https://lnkd.in/eyNPriA9

#Neuroscience #Myelin #MultipleSclerosis #BrainHealth #NeuralEngineering

🔋 Lysosomes work by maintaining a highly acidic internal environment. That acidity requires constant energy, specifically an ATP-consuming proton pump that continuously pushes hydrogen ions into the lysosome to keep it acidic enough to activate its digestive enzymes (red lysosomes).

Here’s what happens near a chronically implanted electrode.

🪫 The metabolic stress described in previous posts, reduced tissue oxygenation, disrupted blood flow, energetically depleted neurons, compromises the cell’s ability to run that proton pump. When the pump slows, the lysosome becomes less acidic. When it becomes less acidic (yellow and green), the digestive enzymes stop working properly. Cellular waste that should be broken down and recycled instead accumulates as a granular material called lipofuscin, sometimes called the age pigment because it accumulates naturally in very old cells. (This is not something you can study in NAMS, because it requires a fully integrated and self-contained metabolic system.)

🔬 We found lipofuscin accumulation in neurons and glial cells near chronically implanted electrodes in patterns that correlated with metabolic stress, not simply with time or neuronal death. In other words, cells that appeared alive and structurally intact were carrying a waste burden consistent with severe metabolic dysfunction.

🔎 This matters for two reasons. First, lysosomal dysfunction is a central feature of Alzheimer’s disease, Parkinson’s disease, ALS, and several other neurodegenerative conditions. The cellular pathway we’re observing near implanted electrodes overlaps significantly with disease pathways. Second, it suggests a potential intervention target: if we can restore metabolic supply and lysosomal function near the electrode, we may be able to prevent or reverse the cellular deterioration that silences neurons over time.

🚧 The trash piles up quietly. By the time it’s visible in recordings, the problem has been building for weeks.

Lysosome: https://lnkd.in/eEraH5Fv
Lipofuscin: https://lnkd.in/g6vNw8NP
Metabolic: https://lnkd.in/eZ_7ZsTN
Review: https://lnkd.in/e7MrVCc7

#Neuroscience #Neurodegeneration #CellBiology #BrainHealth #Bioengineering #Lysosomes

Thanks to Bin He for organizing.

BCI failure is not primarily a materials problem. Signal loss begins before glial scar maturation, and two shanks on the same Utah array, 400 µm apart, identical in geometry, stiffness, surface chemistry, and insertion velocity, show completely different tissue responses. That variability alone should have ended the materials-first narrative years ago.

The tissue-electrode interface is an actively remodeling microenvironment. Three biological axes drive that remodeling, none addressed by smaller, softer, or more biocompatible materials.

🧠 Axis 1: Neurovascular disruption Every insertion severs capillaries and ruptures the BBB. Pericyte loss follows within days, capillaries constrict from ~5-6 µm to ~3.5 µm, and the resulting metabolic deficit silences neurons within 100 µm of the implant without killing them.

⚡ Axis 2: Glial reactivity beyond the scar The morphological scar extends ~50 µm. Functional changes in excitability and synaptic function extend beyond 300 µm. Your LFP is partly glial. Decoding models trained on week 1 assume a stable neural population that no longer exists by week 4.

🔬 Axis 3: Oligodendrocyte metabolic failure Demyelination begins within days. Clemastine improves chronic recording without reducing glial scar. A FUS conditional knockout increasing oligodendrocyte cholesterol biosynthesis improved recording again, but myelin sheath thickness did not predict it. Cholesterol biosynthesis activity, not wrapping, maps to performance.

🔥 On inflammation We study the inflammatory response extensively. This talk focused on what it drives downstream: how glial activation alters neurocomputation at the tissue-electrode interface. The inflammatory cascade is the upstream input; circuit-level dysfunction is the output that determines device performance.

💰 On funding Proposed NIH cuts, NOFO collapse, and multi-year funding compression are squeezing pay lines from ~15-20% to ~3-5%. Industry will not fund pre-competitive biological questions. Two actions if you are a U.S. taxpayer:

NIH RFI (deadline May 16) https://www.bioniclab.org/news/request-for-information-nih

Contact representatives on FY2027 appropriations: NOFO collapse and multi-year funding mechanisms

If you work in clinical neurotechnology with unexplained failure patterns, or are a basic neuroscientist with no engineering translation path, reach out.

#NeuralEngineering #BrainComputerInterface #Neuroscience #NIHFunding #BasicScience

📋 Brain-computer interface clinical trials are enrolling participants without routinely screening for genetic risk factors (which adds significant cost). At the same time, we have data showing that implanting an electrode into the brain of a mouse that carries Alzheimer’s risk genes triggers amyloid plaque accumulation and disease pathology months earlier than it would have developed naturally.

🔬 Let me be precise about what that means and what it doesn’t mean.

In our experiments, we implanted microelectrodes into two-month-old mice carrying genetic mutations (APP/PS1) associated with familial Alzheimer’s disease (This can’t be done in NAMS, because NAMS lack the full metabolic system that Alzheimer’s disease exploits). These mice don’t normally develop MX04-labeled Alzheimer’s plaques until four to five months of age. Following electrode implantation, we observed plaque accumulation and markers of Alzheimer’s pathology at two months, two to three months ahead of the typical timeline. The focal brain injury from implantation appeared to accelerate disease progression in animals already on a genetic trajectory toward neurodegeneration.

🚫 This does NOT mean that BCI implants cause Alzheimer’s disease in healthy humans. It means that in a brain already moving toward neurodegeneration, a focal injury event, including but not limited to electrode implantation, may accelerate that progression.

🩺 The implication for clinical trials is not that we should stop enrolling participants. It is that we should know something about the metabolic and genetic landscape of the brain we are implanting into. A 35-year-old with a family history of aggressive early-onset Alzheimer’s and a 35-year-old without that history may respond to the same implant procedure very differently. We don’t currently have the data to know the magnitude of that difference in humans, which is precisely why we need to start asking the question systematically.

🦺 I raise this not to alarm anyone currently enrolled in a BCI trial 🌟the devices have strong safety records for the populations studied🌟 but because science done in mice has a way of becoming relevant in humans, and the time to think about it is before, not after, problems emerge.

AD: https://lnkd.in/g6vNw8NP

#Alzheimers #Neurodegeneration #BrainHealth #ClinicalTrials #Neuroscience #Neurotechnology #BCI

🚫 That assumption is wrong. Or rather, it is far too simple, and the oversimplification has shaped the design of every therapeutic stimulation device currently in clinical use.

🔎 Here’s what we found. When you deliver electrical pulses to the brain through a microelectrode, you don’t just activate nearby neurons. At certain frequencies and temporal patterns, you inhibit neural network activity. Not individual neurons, the biophysics of direct cathodic stimulation make it nearly impossible to inhibit a single cell with an extracellular electrode. But networks? Networks can absolutely be inhibited, through a mechanism that exploits something the field had been overlooking: inhibitory neurons.

🛑 Inhibitory interneurons, particularly the parvalbumin-expressing fast-spiking type, can sustain firing rates above 100 Hz. Excitatory neurons typically cannot reliably fire above 15-20 Hz. When you deliver high-frequency stimulation, you preferentially drive inhibitory networks. If you then pause at the right moment, while excitatory neurons are in their absolute refractory period, the inhibitory drive suppresses excitatory activity during the pause. The result is a net reduction in network output, inhibition, achieved through stimulation.

We demonstrated this using in vivo two-photon calcium imaging, watching the activity of individual labeled neurons in living mouse cortex during and after stimulation. The finding overturned dogma that had stood unchallenged since the early 20th century.

The finding has direct clinical relevance. Depression, epilepsy, schizophrenia, and chronic pain all involve excitation-inhibition imbalances. If stimulation can be used not just to activate but to selectively suppress overactive circuits, the therapeutic possibilities expand considerably.

It also explains something BCI users know experientially but researchers struggled to account for: that the sensation evoked by electrical stimulation fades. The inhibitory recruitment we identified is one mechanism underlying that fading, and understanding it is the first step toward designing stimulation patterns that sustain perception rather than letting it decay.

More to come.

Review: https://lnkd.in/enHUqypN
Inhibitory: https://lnkd.in/ecFihBRm
Temporal Pattern:https://lnkd.in/dXkpMmQ
Freq: https://lnkd.in/e2d39Dvc
Waveform: https://lnkd.in/e-2b4Jq5
Biomimitic: https://lnkd.in/gm2x_AgM

#Neuroscience #Neuromodulation #BrainStimulation #Neurotechnology #BrainComputerInterface

⚠️ The BCI field has operated for decades as though it were. The standard way to evaluate tissue health near an implanted electrode is to count cells and measure impedance. Neurons present, spikes detectable, device biocompatible. That framework misses something fundamental.

🧱 Neurons don’t encode information alone. They encode it through coordinated activity with their neighbors, through precise timing relationships in local circuits. A neuron that fires but has lost its functional coupling to the surrounding network is, from a decoder’s perspective, noise.

💑 We tested this directly. Using chronically implanted arrays in mouse cortex, we tracked whether pairs of neurons maintained correlated firing patterns over weeks. Functional connectivity, how reliably one neuron’s activity predicts another’s, degraded substantially near the electrode, even among neurons that remained individually detectable. They were alive. Spiking. But uncoupled from their neighbors. The local circuit was fragmented.

📉 The degradation was layer-dependent. Different cortical layers showed different vulnerability profiles, meaning the failure is structured, not random. Any intervention treating all cortical tissue as equivalent will miss the mark.

🎞 This reframes what “biocompatibility” should mean for neural interfaces. The traditional definition (does the tissue survive?) is necessary but insufficient. What matters is functional biocompatibility: does the tissue still compute? (FDA definition of biocompatibility is functional)

📊 Our data say that for tissue closest to the electrode, the answer is progressively no, and this functional degradation occurs before the structural markers the field relies on would raise concern. By the time histology looks bad, the network has been impaired for weeks.

🗓 Connect this to earlier posts. Oligodendrocyte injury, vascular disruption, lysosomal dysfunction, each can independently degrade functional connectivity without killing the neuron. Together they create a microenvironment where neurons survive as individuals but fail as a network.

🎥 Recording quality cannot be evaluated by spike count alone. We need metrics that capture whether recorded populations retain their network structure. A channel that detects a neuron is not the same as a channel that detects a neuron doing something meaningful.

Longitudinal Functional connectivity: https://lnkd.in/ePjwGw2S
Alive but Silenced: https://lnkd.in/e6bgMBAt
Review: https://lnkd.in/eYi75Sxi

#Neuroscience #Neurotechnology #BrainComputerInterface #NeuralEngineering #Bioengineering #FunctionalPerformance

The brain is the most metabolically demanding organ in the body. It consumes roughly 20% of the body’s energy despite representing only 2% of its mass. That energy is delivered through a dense network of blood vessels, regulated in real time by a system called neurovascular coupling, the mechanism by which active brain regions signal their need for more blood flow and receive it within seconds.

🚧 When an electrode is implanted, this system is disrupted. Vessels are severed or compressed during insertion. Pericytes, the cells that regulate capillary diameter and blood flow, constrict in response to injury. The result is a local reduction in tissue oxygenation around the electrode in the days and weeks following implantation.

🔇 We showed that this deoxygenation has direct consequences for neural activity. Neurons adjacent to the implant are silenced, not because they are dead or damaged in the conventional sense, but because they lack the metabolic resources to sustain activity. When we provided strong direct electrical stimulation, those neurons responded. They were alive. They were just quiet, rationing energy the way any system does when its supply is constrained.

😶 This has a deeply uncomfortable implication for how we interpret BCI recordings. When a researcher or clinician observes decreased neural activity around a chronically implanted electrode, the standard interpretation is neuronal loss. Our data suggest that at least some of what looks like neuronal loss is actually neuronal silence driven by metabolic stress. The neurons are there. They’ve just gone dark.

🩺 The distinction matters enormously for intervention strategy. If neurons are dead, you need to prevent death. If neurons are metabolically suppressed, you potentially need to restore the energy supply, a very different problem with a very different solution.

🔬 This is why my lab has become increasingly focused on oligodendrocytes, pericytes, and the neurovascular system as targets, not just the electrode-tissue interface itself.

Metabolic Stress & Silencing: https://lnkd.in/e6bgMBAt
Review: https://lnkd.in/e7MrVCc7
Pericytes: https://lnkd.in/edzheqNu
Oligo: https://lnkd.in/ePXYRr2C
Metabolic Stress& Silencing2: https://lnkd.in/eZ_7ZsTN
Metabolic Stress3: https://lnkd.in/e8FdNNFw
Review 2: https://lnkd.in/e_giHFkU

#Neuroscience #BrainHealth #Metabolism #BrainComputerInterface #Bioengineering

⏳ That framing was wrong, and it cost the field decades.

My lab has spent years studying the non-neuronal cells of the brain, oligodendrocytes, astrocytes, microglia, pericytes, and what we’ve found repeatedly is that these cells are not passive bystanders to what’s happening at the electrode interface. They are active participants in determining whether the device continues to work.

🔎 Oligodendrocytes are perhaps the most striking example. These cells wrap axons in myelin, the insulating sheath that most people know as the thing that speeds up nerve conduction. The standard story is that myelin is about speed. That’s true, but it’s incomplete.

🔬 We discovered something more fundamental. Oligodendrocytes dramatically reduce the metabolic cost of neural activity. Every time a neuron fires an action potential, sodium and potassium ions cross the membrane and have to be pumped back. That pumping requires ATP. Myelin restricts where that ion exchange happens, dramatically reducing the total energy bill for sustained neural firing.

😫 When oligodendrocytes are depleted near an implanted electrode, neurons don’t slow down. They fatigue. They can’t maintain elevated firing rates under sustained input for more than a fraction of a second. The device is recording from neurons that have, in metabolic terms, run out of fuel.

🧩 This finding reframed an observation that had puzzled BCI researchers for years: why do recordings degrade even when the electrode looks fine and neurons are still alive nearby? Part of the answer is oligodendrocytes. The neurons are there. They’re just exhausted.

Oligo Review: https://lnkd.in/edpJ2zzy
Oligodendrocyte Precursor Cells: https://lnkd.in/eyz34b4
Oligodendrocytes: https://lnkd.in/ePXYRr2C
Oligo Failures/Fatigue: https://lnkd.in/egAwPGv

#Neuroscience #Neurotechnology #Glia #BrainHealth #NeuralEngineering #BCI #Neurotech

📈 BCIs are having a moment. Billions in private capital. Headlines about paralyzed patients moving cursors & typing text. Real progress, built by talented engineers solving hard problems.

🦯 But here’s what most people don’t see.

🛫 Every one of those achievements depends on basic science discoveries made 20~30 yrs ago. Publicly funded research that characterized how neurons fire, how electrodes interact with tissue, how the brain reorganizes after injury. That knowledge is the runway. The devices are the aircraft.

🚧 Right now, we are building faster planes on a runway that nobody is extending.

🔬 I’ve spent 20 years studying what happens at the boundary between implanted devices & living brain tissue. The biology is humbling. Glial cells encapsulate electrodes. Blood vessels rupture and never fully recover. Neurons die or get displaced. The immune system mounts a chronic response that degrades signals over months~years.

🧬 These are not engineering problems. You cannot solve them with better materials or more channels or faster decoding algorithms. They are biological problems, & they require basic science to understand.

💳 Venture capital will not fund this work. There is no quarterly earnings case for astrocyte biology. No Series B for characterizing neurovascular disruption at the electrode interface. That is not a criticism of VC. It is a description of what VC is designed to do, which is build products, not generate foundational knowledge.

🏥 NIH is the only institution with both the mandate and the scale to fund this kind of research. And right now, OMB is freezing NIH funding. Paylines are compressed. Review panels increasingly penalize DISCOVERY-oriented proposals that cannot promise translational outcomes within 5 yrs. Funding delays disproportionately hit new grants.

🇨🇳 Meanwhile, other nations are investing heavily in exactly this space with explicit patience for long-term discovery. We should not assume that competitors lack the capacity for original scientific contribution. History has repeatedly punished that assumption.

🔎 Every unfunded basic science grant cycle means specific biological questions about chronic BCI failure go unanswered. Those unanswered questions become the ceiling on what the next generation of devices can achieve, regardless of how much private capital flows into engineering.

⏱️ Translation without basic science is a plane accelerating toward the end of a runway that gets shorter every year.

If we want BCIs that last a lifetime in the human brain, we need to fund the science that explains why they currently don’t.

https://www.bioniclab.org/links/basicscience

#neurotech #BCI #NIH #basicscience #discovery #WhyBCIsFail ##Innovation #Neurotechnology #BrainComputerInterface #NeuralEngineering #Bioengineering #FunctionalPerformance #Neuroscience

🗓️ Over the first few days following implantation, microglia migrate their cell bodies toward the injury site. Astrocytes, star-shaped support cells that normally maintain the chemical environment around neurons, swell and extend processes toward the device. NG2 cells, precursors to several cell types, begin dividing and moving in. Pericytes, the cells that regulate blood flow through capillaries, constrict nearby vessels. Within a week, the electrode is encapsulated in a dense cellular sheath.

⛔ This process, the foreign body response, is the brain doing exactly what it should do when faced with an injury it cannot remove. The problem is that the brain cannot distinguish between a harmful splinter and a therapeutic device. It treats them identically.

🦠 The cellular sheath that forms around a chronically implanted electrode does several things that are bad for recording. It increases the electrical impedance between the electrode and the neurons it’s trying to listen to. It pushes neurons physically away from the recording site. And it creates a chronically inflamed microenvironment that is toxic to the very cells the device is trying to monitor.

🤝 What surprised us most in studying this process wasn’t the glial response itself, that was well known. It was the timing. The different cell types respond on very different time scales: microglia within minutes, astrocytes within hours, NG2 cells within days. This orchestration matters because it means there are distinct windows during which intervention might redirect the response. A drug delivered on day one would encounter a very different biological environment than the same drug delivered on day seven.

🕰️ The field spent decades trying to make electrodes that the brain would ignore. We’ve had to accept a harder truth: the brain will not ignore a foreign object. The goal has to shift from avoiding the response to redirecting it.

Microglia: https://lnkd.in/e6Uc4YPw
Astrocytes: https://lnkd.in/e2wFzPCT
NG2: https://lnkd.in/eyz34b4
Oligodendrocytes: https://lnkd.in/ePXYRr2C
Pericytes: https://lnkd.in/edzheqNu
Neuron: https://lnkd.in/enJAmMwi
Neuronal Silencing: https://lnkd.in/e6bgMBAt
Review 1: https://lnkd.in/e7MrVCc7
Review 2: https://lnkd.in/ebB5H4K

#Neuroscience #BrainComputerInterface #Immunology #NeuralEngineering

🧠 Every time the brain moves, and it moves constantly (with every heartbeat, every breath, every shift in posture), a rigid electrode anchored to the skull shifts relative to the soft tissue around it. This micromotion is measured in microns, but at the cellular scale, microns matter. Cells at the electrode surface experience repeated mechanical strain. Blood vessels are tugged. The tissue never reaches equilibrium because the mechanical insult never stops.

🗺️ We mapped the design landscape for this problem in a systematic review of how material properties (stiffness, size, surface chemistry, geometry) interact with the biological response. The picture that emerged was sobering. No single material parameter predicts outcome. Stiffness interacts with cross-sectional area. Surface chemistry interacts with geometry. The design space is high-dimensional, and most of it is unexplored.

🔍 One approach our lab pioneered was moving to carbon fiber microelectrodes. These are roughly 7 microns in diameter, thin enough that the tissue can move around them rather than being displaced by them. We showed in Nature Materials that these ultrasmall probes could record single-unit neural activity with dramatically less tissue displacement during insertion and reduced chronic inflammation compared to conventional silicon devices.

📑 But here is the harder lesson. Making electrodes smaller and more flexible helps. It does not solve all the problem. Even our carbon fiber probes, among the smallest functional recording electrodes ever implanted, still trigger a biological response. The foreign body reaction described in the next post occurs around flexible devices too, just at reduced magnitude. The brain does not distinguish between a large insult and a small one in kind, only in degree.

⏳ This is why materials science alone cannot fix BCI longevity. Better materials buy time. They reduce the severity of the initial injury and the magnitude of the chronic response. But they do not eliminate the biological cascade that ultimately determines whether the device keeps working. Understanding that cascade requires looking past the electrode and into the cells surrounding it.

Ultrasmall Electrodes: https://lnkd.in/epWswUdi
Mechanical: https://lnkd.in/etnqjYRA
Size and Neuron: https://lnkd.in/ei2W5HyW
Review 1: https://lnkd.in/e7MrVCc7
Review 2: https://lnkd.in/eW3rAXGB

#Neuroscience #Neurotechnology #BrainComputerInterface #MaterialsScience #Bioengineering #micro #nano

🦠 The moment an electrode enters brain tissue, something remarkable happens. Microglia, the brain’s resident immune cells, extend their processes toward the insertion site within seconds to minutes. Not hours. Seconds. We watched this happen in real time using two-photon microscopy, imaging living mouse brain through a small window in the skull as the electrode descended. The microglia moved like fingers reaching toward a splinter.

⌛ This immediate response sets the stage for everything that follows. The brain doesn’t wait to see whether the device is harmful. It treats any foreign object as a threat and begins responding before any damage has even been assessed.

🚧 At the same time, nearby blood vessels, some severed during insertion, others simply compressed as tissue deforms, begin to leak. The blood-brain barrier, the brain’s carefully maintained boundary between circulation and neural tissue, is disrupted. Proteins that normally stay in the bloodstream spill into brain tissue, and this triggers a cascade of inflammatory signals.

⚠️ Here’s what this means practically: two electrodes implanted by the same surgeon, in the same brain region, with the same device, on the same day, can perform very differently. Not because of anything that happened after implantation, but because of what happened during the ten seconds it took to insert them. Which blood vessels were nicked. How much the tissue compressed. Whether the trajectory grazed an arteriole or threaded between capillaries.

🔦 We were the first to show that this insertion variability has lasting consequences for how the device performs months later. That finding helped inform image-guided surgical approaches now used in next-generation BCI systems.

📣 The engineering implication is uncomfortable: even a perfect device, perfectly fabricated, can be compromised in the operating room before it ever records a single spike.

Blood Vessels: https://lnkd.in/ekVrUTmp
Microglia: https://lnkd.in/efv-dkfr
Astrocytes: https://lnkd.in/e2wFzPCT
Oligodendrocyte Precursor Cells: https://lnkd.in/eyz34b4
Engineering: https://lnkd.in/epWswUdi

#Neuroscience #Bioengineering #BrainComputerInterface #Immunology #NeuralEngineering